More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

S&P DJI Announces March 2022 Quarterly Rebalance

Mar 4, 2022 at 6:22 AM EST · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Mar 4, 2022 at 6:22 AM EST · 10 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2022-quarterly-rebalance-120

Recce Pharmaceuticals Ltd. on 6ix

Story so far

  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021

Earlier from Recce Pharmaceuticals

  • Positive Safety Continues in 3rd Cohort PhI Clinical TrialFeb 20, 2022
  • Positive Safety Data from Third Cohort of PI Clinical TrialFeb 7, 2022
  • Positive Safety Data from Second Cohort of PI Clinical TrialJan 18, 2022
  • Positive Safety Data from Phase 1 Clinical TrialJan 6, 2022
  • Patients to be Dosed in Ph 1 IV Clinical Trial of R327Dec 14, 2021

Later from Recce Pharmaceuticals

  • Safety Committee Clears PhI R327 Dose IncreaseMar 6, 2022
  • $3.08m R&D Rebate ReceivedMar 28, 2022
  • Positive safety data from 4th Cohort -Phase I Clinical TrialMar 29, 2022
  • Anti-Viral Patent Granted in Hong KongApr 11, 2022
  • Phase I Clinical Trial R327 Advances to High Dose CohortApr 12, 2022
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer